Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Circulating Mirnas Can Serve As Potential Diagnostic Biomarkers in Chronic Myelogenous Leukemia Patients Publisher



Keramati F1 ; Jafarian A2 ; Soltani A3, 4 ; Javandoost E5 ; Mollaei M6 ; Fallah P7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of biotechnology, college of science, university of Tehran, Tehran, Iran
  2. 2. Iranian Tissue Bank Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. CinnaGen Medical Biotechnology Research Center, Alborz University of medical sciences, Karaj, Iran
  4. 4. CinnaGen Research and Production Co., Alborz, Iran
  5. 5. Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  6. 6. Department of Immunology, School of medicine, Tarbiat Modares University, Tehran, Iran
  7. 7. Department of Clinical Laboratory Sciences, Alborz University of Medical Sciences, Karaj, Iran

Source: Leukemia Research Reports Published:2021


Abstract

Introduction: Chronic Myelogenous Leukemia (CML) is a myeloproliferative disorder described as a malignant blood disorder by accounts for 15–20% of all adult leukemia. MicroRNAs (miRNAs) play an important role in post-transcriptional regulation of gene expressions. Expression level of tumor suppressor-miRNAs, described as miRNAs that target the oncogens, can contribute to diagnosis and prognosis of some malignant disorders including CML. We theorized that according to the excessive proliferation and alteration in miRNA expressions, there could be a change in the expression of miRNAs in plasma carried by exosomes. Methods: We consequently decided to detect the differences between normal and aberrant miRNA expression in human plasma sample to find out the possibility of diagnosis by these alterations. The expression of candidate miRNAs were compared using RNA extracted from the plasma of 50 patients, as well as 30 healthy individuals. We analysed the plasma miR-16-1, miR-20, miR-106, miR-126, miR-155, miR-222, and miR-451 expression levels in CML patients by individual real-time quantitative RT-PCR. Results: All selected miRNAs were found to be upregulated in newly diagnosed CML patients compared to the control, while upregulation of only three (miR-20, 106 and 222) were significant (17.4, 19 and 74.95 fold change, respectively; p<0.0001). In conclusion: microRNAs have a potential use in treatment of CML, as they can target the genes involved in cell cycle, MAPK, growth inhibition, TGF beta, and p53 signaling pathways. Therefore, these miRNA signatures provide the basis for their utilization as biomarkers in CML. © 2021